# Macrophage Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/macrophage-pharma

- Industry: Pharmaceuticals
- Headquarters: Windsor, UK
- Website: www.macrophagepharma.com
- Total disclosed funding: $17M
- Latest round: Series A (Aug 23, 2017)
- Investors on record: 4

## About

Macrophage Pharma Limited develops innovative biopharmaceutical solutions focusing on immune modulation and cancer therapy, aiming to enhance patient outcomes through advanced therapies targeting complex diseases.Founded in 2014 in Windsor, UK, Macrophage Pharma Limited specializes in biopharmaceutical solutions that leverage the immune system to fight cancer. The company has raised GBP 3.44 mn in Series A funding from M Ventures as part of its growth strategy, valuing it at GBP 25.52 mn. The firm has completed a total of 2 deals, with the most recent occurring on August 23, 2017. CEO Søren Bregenholt leads the company, which has not disclosed any subsidiaries or significant pivots in its operational strategy since its inception.Macrophage Pharma specializes in innovative biopharmaceutical solutions targeting immune modulation and cancer therapy. Their core product offerings focus on developing therapies that harness the body's immune system to effectively combat various diseases, primarily cancer. These products are designed to enhance immune response and improve patient outcomes in complex conditions where traditional therapies may fall short. The company aims to serve a diverse clientele that includes hospitals, healthcare providers, and research institutions, with end users being patients suffering from chronic diseases and cancer. Macrophage Pharma's products are currently marketed in North America and select European countries, focusing on regions where advanced healthcare systems are in place, facilitating access to cutting-edge therapies.In the most recent year of 2017, Macrophage Pharma reported no revenue, with an EBITDA loss of GBP 3,204,570.30. The company generates revenue through collaborative partnerships and direct sales to medical institutions, engaging primarily in B2B transactions. Their flagship products are offered through subscription models or one-time purchase agreements, facilitating long-term relationships with healthcare providers.Macrophage Pharma plans to utilize the GBP 3.44 mn raised in Series A funding to further develop its product pipeline and explore new markets. The company is focusing on launching new therapies aimed at enhancing immune responses and is specifically targeting expansions into additional European and North American markets by 2020. The recent funding will support these initiatives, allowing for continued innovation in biopharmaceutical solutions.

## Funding rounds

- Series A, Aug 23, 2017, $4.4M — M Ventures
- Series A, Nov 29, 2016, $12M — Aglaia Oncology Funds, Sixth Element Capital, Novo Seeds

## Investors

- Aglaia Oncology Funds (https://capitalatlas.ai/funds/aglaia-oncology-funds) — Series A
- Sixth Element Capital (https://capitalatlas.ai/funds/sixth-element-capital) — Series A
- Novo Seeds — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A